Skin Reactions and Allergies with Nifedipine and Entresto
Both nifedipine and Entresto (sacubitril/valsartan) can cause skin reactions and allergic manifestations, with Entresto carrying a specific FDA warning for serious allergic reactions including angioedema, while valsartan (a component of Entresto) has documented cases of exanthematous drug eruptions and photosensitive rashes.
Entresto (Sacubitril/Valsartan) Skin and Allergic Reactions
Serious Allergic Reactions - Angioedema
- Angioedema is the most clinically significant allergic reaction associated with Entresto, occurring in 0.5% of patients in clinical trials 1.
- The FDA label explicitly warns about serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death 1.
- Black patients face substantially higher risk, with angioedema occurring in 2.4% of Black patients treated with Entresto compared to 0.5% with enalapril 1.
- Patients with prior angioedema history have elevated risk of recurrence when taking Entresto 1.
Other Hypersensitivity Reactions
- Postmarketing surveillance has identified additional hypersensitivity reactions including rash, pruritus, and anaphylactic reactions 1.
- An unusual but documented adverse effect is persistent nasal pruritus, which resolved upon discontinuation in case reports 2.
Valsartan Component-Specific Reactions
- Exanthematous drug eruptions have been documented with valsartan, presenting as diffuse, itchy erythematous maculopapular eruptions 3.
- Histopathologic findings in valsartan-induced eruptions show lymphocyte exocytosis, spongiosis, necrotic keratinocytes, and perivascular eosinophils 3.
- A case report documented combined angioedema and photosensitive pruritic rash after 3 months of valsartan therapy 4.
Critical Safety Considerations
Contraindications Related to Allergic Risk
- Entresto is absolutely contraindicated in patients with prior allergic reactions including facial swelling, lip swelling, tongue swelling, throat swelling, or breathing difficulty while taking ACE inhibitors or ARBs 1.
- A mandatory 36-hour washout period is required when switching from ACE inhibitors to minimize angioedema risk 1, 5.
- Recent switchers from ACE inhibitors or ARBs to Entresto face increased angioedema risk compared to new users (HR 1.98 and 2.45 respectively for recent switchers) 6.
Emergency Management Protocol
- Immediate discontinuation and emergency medical attention are required if angioedema symptoms develop 1.
- Patients should never restart Entresto after experiencing angioedema 1.
- Treatment involves subcutaneous epinephrine, intravenous methylprednisolone, and diphenhydramine for acute reactions 4.
Nifedipine Considerations
While the provided evidence does not contain specific FDA labeling or guidelines for nifedipine skin reactions, calcium channel blockers as a class are known to cause cutaneous side effects. When combined with Entresto, the therapeutic combination has been studied for efficacy in diabetic nephropathy with hypertension without specific safety signals regarding additive skin reaction risk 7.
Clinical Monitoring Recommendations
- Counsel all patients starting Entresto about angioedema signs and symptoms, emphasizing the need for immediate medical attention 5.
- Black patients require heightened vigilance given their 2.4% angioedema incidence 1.
- Any facial swelling, lip swelling, tongue swelling, throat tightness, or breathing difficulty warrants immediate drug cessation and emergency evaluation 1.
- Patients developing rash, pruritus, or other hypersensitivity manifestations should be evaluated for drug discontinuation 1.